UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of February 2021 (Report No. 4)
Commission file number: 001- 38041
SCISPARC LTD.
(Translation of registrant’s name into English)
16 Abba Hillel Road
Ramat Gan 5250608, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____
CONTENTS
On February 17, 2021, SciSparc Ltd. (the “Company”) issued a press release titled: “SciSparc to Conduct a Phase IIa Clinical Trial in Alzheimer’s Patients Using the Company’s Proprietary Cannabinoid-Based Treatment.” A copy of this press release is furnished herewith as exhibit 99.1.
1
EXHIBIT INDEX
Exhibit No. | ||
99.1 | Press release titled: “SciSparc to Conduct a Phase IIa Clinical Trial in Alzheimer’s Patients Using the Company’s Proprietary Cannabinoid-Based Treatment.” |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
SciSparc Ltd. | |||
Date: February 17, 2021 | By: | /s/ Oz Adler | |
Name: | Oz Adler | ||
Title: | Chief Financial Officer |
3